Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Harvard Bioscience, Inc. (HBIO) Names Jeffrey A. Duchemin To The Additional Roles Of President And Director 0 comments
    Nov 5, 2013 1:48 PM | about stocks: HBIO

    Global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, Harvard Bioscience announced that its Chief Executive Officer, Jeffrey A. Duchemin, has been appointed to the additional positions of President and Director, effective immediately. He is set to replace David Green, who became the President of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a spin off from HBIO, on November 1, 2013. Green will remain on the Board of Directors of Harvard Bioscience.

    David Green stated, "Guiding Harvard Bioscience successfully into its future requires a leader with profound understanding of the life sciences industry, a specific grasp of its customer base, and the know-how to expand the Company's growth internationally. In the few months since he took the helm of HBIO as Chief Executive Officer, Jeff has proven himself eminently qualified for this position, and I look forward to watching him continue to grow the Company."

    Jeffrey A. Duchemin commented, "As President and Chief Executive Officer of Harvard Bioscience, I intend to implement a comprehensive set of goals that includes overseeing the organic growth of the Company, embarking on a program of geographic expansion and managing strategic growth via acquisitions. I have already begun to assemble a key team of managers to assist me in this goal, and I look forward to sharing key milestones with shareholders as we move ahead. I would also like to thank David Green for his years of dedication to Harvard Bioscience and for contributing to its success."

    Prior to joining Harvard Bioscience as the Chief Executive Officer this August, Duchemin spent 16 years with Becton Dickinson (BD) in progressive sales, executive leadership and marketing positions across the company's three business segments: BD Biosciences, BD Medical Systems, and BD Diagnostic Systems. In October of 2012, BD Biosciences, Discovery Labware was acquired by Corning Life Sciences. Duchemin was previously a Global Business Director for Corning Life Sciences until leaving to take a position with Harvard Bioscience. A results driven leader, the depth of his expertise spans across a broad range of life science research and medical device products, resulting in impressive growth on an international basis. Duchemin holds an M.B.A. from Southern New Hampshire University and a Bachelor of Science degree from the University of Massachusetts Dartmouth in accounting.

    On an additional note, Harvard Bioscience announced that the position of Chief Operating Officer is to be eliminated as of November 30, 2013. Duchemin is set to take on the responsibilities of that position.

    To learn more, please visit harvardbioscience.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: HBIO
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.